3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
15
Phase 2
12
Phase 1/2
2
Phase 2/3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
1
Breast
1
Conditions
Inflammatory Breast Neoplasms
1
Carcinoma, Ductal, Breast
1
Interventions
Capecitabine
17
Paclitaxel
16
Docetaxel
13
Carboplatin
12
Cyclophosphamide
11
Gemcitabine
9
Epirubicin
9
Trastuzumab
8
Letrozole
8
Doxorubicin
7
pertuzumab
5
Cisplatin
5
Vinorelbine
4
130-nm albumin-bound paclitaxel
4
exemestane
3
Zoledronic Acid
3
Tamoxifen
3
Neoadjuvant Therapy
3
Lapatinib
3
Injections
3
Drug Therapy
3
Ado-Trastuzumab Emtansine
3
AC protocol
3
pyrotinib
2
palbociclib
2
camrelizumab
2
apatinib
2
Thiotepa
2
Taxes
2
Standard of Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gonadotropin-Releasing Hormone
×
Breast
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled